Peña-Alonso YR, Romano-Mazzotti L, Pacheco-Ríos A

Idioma: Español
Referencias bibliográficas: 22
Paginas: 373-381
Archivo PDF: 368.25 Kb.

FRAGMENTO

Caso A-2004-02
Adolescente masculino de 14 años de edad quien fue referido al hospital de una organización no gubernamental cuatro días antes de su muerte por presentar dificultad respiratoria.
Entre sus antecedentes se refiere que el padre falleció a los 24 años de edad por virus de inmunodeficiencia humana/síndrome de inmunodeficiencia adquirida (VIH/SIDA) y la madre, de 18 años de edad, abandonó al paciente cuando tenía seis meses de vida. La madre adoptiva tenía 52 años, escolaridad primaria y no padecía ninguna enfermedad; se ignoraba el parentesco con el paciente. Se desconocen otros antecedentes heredofamiliares.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children (U.S.), United States. Health Resources and Services Administration. National Institutes of Health (U.S.). Guidelines for the use of antiretroviral agents in pediatric HIV infection; 2008 Junio 28; Bethesda, MD: National Institutes of Health; 2008.

2. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: WHO Press; 2007.

3. Guia de Manejo Antirretroviral de las Personas con VIH. Mexico, D.F.: Secretaria de Salud; 2007.

4. American Academy of Pediatrics. Human immunodeficiency virus infection. En: Pickering LK, Baker CJ, Long SS, Mc Millan JA, editores. Red Book: 206 Report of Committe on Infections Diseases. 27th ed. Elk Grove Village, III: American Academy of Pediatrics; 2006. p. 378-401.

5. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41: 1-19.

6. Shikuma CM, Valcour VG, Ratto-Kim S, et al. HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages? Clin Infect Dis. 2005; 40: 1846-8.

7. Kotler D, Wanke C. Management of HIV wasting syndrome: a consensus conference. J Acquir Immune Defic Syndr. 2004; 37 Suppl 5: S261.

8. Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003; 36: S69-78.

9. Corcoran C, Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1999; 340: 1740-50.

10. Wanke CA, Silva M, Ganda A, et al. Role of acquired immune deficiency syndrome-defining conditions in human immunodeficiency virus-associated wasting. Clin Infect Dis. 2003; 37 Suppl 2: S81-4.

11. Dworkin MS, Williamson JM. AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr. 2003; 33: 267-73.

12. UNAIDS. Report on the global HIV/AIDS epidemic 2008: executive summary. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2008.

13. El VIH/SIDA en México. 2008. Available from: http://www.censida.salud.gob.mx/interior/cifras.html

14. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008; 300: 51-9.

15. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372: 293-9.

16. Ofori-Mante JA, Kaul A, Rigaud M, et al. Natural history of HIV infected pediatric long-term or slow progressor population after the first decade of life. Pediatr Infect Dis J. 2007; 26: 217-20.

17. De Angelis DS, Freire WS, Pannuti CS, Succi RC, Machado DM. CCR5 genotypes and progression to HIV disease in perinatally infected children. Braz J Infect Dis. 2007; 11: 196-8.

18. Mikhail M, Wang B, Saksena NK. Mechanisms involved in non-progressive HIV disease. AIDS Rev. 2003; 5: 230-44.

19. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, et al. Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS. 2003; 17: 1631-8.

20. Contopoulos-Ioannidis DG, O’Brien TR, Goedert JJ, Rosenberg PS, Ioannidis JP. Effect of CCR5-delta32 heterozygosity on the risk of perinatal HIV-1 infection: a meta-analysis. J Acquir Immune Defic Syndr. 2003; 32: 70-6.

21. Ometto L, Bertorelle R, Mainardi M, et al. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J Infect Dis. 2001; 183: 814-8.

22. Capristo-Gonzalez F, Barragán-Pérez E, Pavía-Ruz N, et al. Manifestaciones neurológicas en pacientes pediátricos y adolescentes mexicanos infectados con VIH/SIDA. Experiencia del Hospital Infantil de México Federico Gómez. Bol Med Hosp Infant Mex. 2008; 65: 6-12.